SCHEMBL1170125

SCHEMBL1170125

NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACE P12821 2/20 0.44
REN P00797 1/20 0.44
F2 P00734 2/20 0.43
FOLH1 Q04609 2/20 0.42
RIMKLA Q8IXN7 1/20 0.42
NAALAD2 Q9Y3Q0 1/20 0.42
CMA1 P23946 1/20 0.42
POLB P06746 1/20 0.41
ITGB1 P05556 1/20 0.40
ITGA4 P13612 1/20 0.40
DPP4 P27487 2/20 0.40
FAP Q12884 2/20 0.40
DPP8 Q6V1X1 2/20 0.40
DPP9 Q86TI2 2/20 0.40
PREP P48147 1/20 0.40
XIAP P98170 1/20 0.39
OPRM1 P35372 1/20 0.39
DPP7 Q9UHL4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1170124 1.00 ACE (0.44) ACERENF2FOLH1RIMKLA
SCHEMBL8255099 0.96 FOLH1 (0.41) ACERENF2FOLH1RIMKLA
SCHEMBL2084204 0.96 FOLH1 (0.41) ACERENF2FOLH1RIMKLA
SCHEMBL17997394 0.91 F2 (0.42) ACEF2ITGB1ITGA4DPP4
SCHEMBL28890641 0.91 F2 (0.42) ACEF2ITGB1ITGA4DPP4
SCHEMBL29832826 0.91 PTPN1 (0.43) ACERENF2CMA1ITGB1
SCHEMBL30563217 0.91 GRB2 (0.42) ACERENF2CMA1ITGB1
SCHEMBL30627048 0.90 ACE (0.44) ACERENF2CMA1ITGB1
SCHEMBL29832765 0.88 PTPN1 (0.42) F2CMA1POLBITGB1ITGA4
SCHEMBL2082150 0.88 XIAP (0.43) F2ITGB1ITGA4DPP4FAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4001 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025149851-A2 METHODS FOR TREATING INFLAMMATORY DISEASES YUYU PHARMA, INC. (KR) 2025-07-17 WO claimed
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
WO-2025042352-A2 SINGLE-CHAIN VARIABLE FRAGMENT (SCFV) MOUSE ANTIBODY SPECIFIC TO SAPOSIN-LIKE PROTEIN 2 OF THE LIVER FLUKE FASCIOLA GIGANTICA BURAPHA UNIVERSITY (TH) 2025-02-27 WO claimed
EP-4493148-A1 PROTEIN HYDROLYSATES OF AZUKI BEANS AND COSMETIC USES THEREOF Lubrizol Advanced Materials, Inc. (US) 2025-01-22 EP claimed
CN-117858890-A Polypeptide compound and application thereof in treating enteritis 四川好医生攀西药业有限责任公司 2024-04-09 CN claimed
CN-117720638-A Recombinant IV type humanized collagen with antioxidant and anti-inflammatory activities 西安德诺海思医疗科技有限公司 2024-03-19 CN claimed
WO-2023175531-A1 PROTEIN HYDROLYSATES OF AZUKI BEANS AND COSMETIC USES THEREOF LUBRIZOL ADVANCED MATERIALS, INC. (US) 2023-09-21 WO claimed
WO-2023080791-A1 PEPTIDES FOR THE INHIBITION OF PARASITE INFECTION KAPP DET GODE HÅP AS (NO) 2023-05-11 WO claimed
CN-110003334-B Polypeptide, CD19 single domain antibody, preparation method thereof, nucleotide sequence and kit 深圳普瑞金生物药业股份有限公司 2023-05-09 CN claimed
WO-2022256800-A2 HUMAN SPERMINE OXIDASE CRYSTAL AND USES THEREOF JANSSEN VACCINES & PREVENTION B.V. (NL) 2022-12-08 WO claimed
US-20150197543-A1 Treatment of Autism Spectrum Disorders Using Glycyl-L-2-Methylprolyl-L-Glutamic Acid NEUREN PHARMACEUTICALS LIMITED (NZ) 2015-07-16 US claimed
CN-104302271-A Moisturizing composition comprising an aminopeptide mixture UNILEVER NV 2015-01-21 CN claimed
WO-2014085480-A1 TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID NEUREN PHARMACEUTICALS LIMITED (NZ) 2014-06-05 WO claimed
US-20140147491-A1 TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID NEUREN PHARMACEUTICALS LIMITED (AU) 2014-05-29 US claimed
EP-2667715-A1 TREATMENT OF AUTISM SPECTRUM DISORDERES USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID Neuren Pharmaceuticals Limited (NZ) 2013-12-04 EP claimed
WO-2012102832-A1 TREATMENT OF AUTISM SPECTRUM DISORDERES USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID NEUREN PHARMACEUTICALS LIMITED (NZ) 2012-08-02 WO claimed
WO-2011037644-A1 CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY NEUREN PHARMACEUTICALS LIMITED (NZ) 2011-03-31 WO claimed
US-20110052531-A1 CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY NEUREN PHARMACEUTICALS LIMITED (AU) 2011-03-03 US claimed
US-7776876-B2 Cyclic G-2Allylproline in treatment of Parkinson's disease NEUREN PHARMACEUTICALS, LTD. (NZ) 2010-08-17 US claimed
US-20060258663-A1 Cyclic G-2AllylProline in treatment of Parkinson's disease NEUREN PHARMACEUTICALS LIMITED (NZ) 2006-11-16 US claimed